HC Wainwright & Co. reiterates Buy rating on Aclaris Therapeutics, $16 price target

What happened

HC Wainwright & Co. reiterated a Buy rating on Aclaris Therapeutics stock with a $16.00 price target, implying 322.2% upside from the October 27 close of $3.79. The note cited positive Phase 1b trial data for ATI-052 and a roughly $50 million equity offering.

Confirmed

Global impact / market context

A $16 target far above the $3.79 close signals the analyst expects the drug developer's shares to multiply if its pipeline succeeds. That gap shows how strongly the call depends on trial results, so any safety or efficacy setback could sharply change the outlook.

Analyst inference

The reiterated rating and capital raise point to continued investor support for Aclaris while it funds ATI-052 testing. The article does not report how the stock traded after the note, so the described upside is the analyst's view rather than an observed market move.

Analyst inference

What to watch

1. Watch Aclaris's progress with ATI-052, its anti-TSLP/IL-4Rα bispecific antibody, which the article says showed promising Phase 1b results in atopic dermatitis and asthma. Confirmed
2. Track whether the roughly $50 million equity offering, which the article says included healthcare-focused funds, is enough to fund the company's clinical programs, especially ATI-052 development. Proposed
3. Monitor future trial data for safety and durable responses, because the $16 price target's 322.2% upside implies the analyst expects strong clinical and commercial success. Analyst inference

Evidence

• Original source link unavailable